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1734Anti-Thymocyte Globulin (Thymoglobulin),
Tacrolimus, and Sirolimus as Acute Graft-versus-Host
Disease Prophylaxis for Unrelated Hematopoietic Stem
Cell Transplantation
Zaid Al-Kadhimi,1 Zartash Gul,2 Roberto Rodriguez,3 Wei Chen,4 Daryn Smith,4
Alice Mitchell,5 Muneer Abidi,1 Lois Ayash,1 Abhinav Deol,1 Lawrence Lum,1,6
Stephen Forman,3 Voravit Ratanatharathorn,1 Joseph Uberti1Acute graft-versus-host disease (aGVHD) is a major cause of morbidity and mortality in patients undergoing
unrelated hematopoietic stem cell transplantation. We prospectively evaluated the efficacy of intermediate-
dose rabbit anti-thymocyte globulin (Thymoglobulin a total of 4.5 mg/kg given over days23,22, and21) in
combination with tacrolimus and sirolimus for the prevention of aGVHD. We enrolled 47 recipients who
underwent unrelated hematopoietic stem cell transplantation. Patients received daily granulocyte colony-
stimulating factor starting on day 16 until neutrophil engraftment (median duration, 11 days; range, 9-15
days). Twenty-two patients received HLA 8/8 and 25 received 7/8 matched grafts, respectively. The median
follow-up duration was 23.6 months (range, 18.8-27.9 months). The cumulative incidence of grade II to IV
aGVHD was 23.4% (95% confidence interval, 12.4-36.3). At 2-year follow-up, the cumulative incidence of
nonrelapse mortality was 31.9%, cumulative incidence of relapse was 24.6%, and cumulative incidence of
chronic GVHD was 33%. Progression-free survival at 1 year was 54%, with a median of 17.7 months. Overall
survival at 1 year was 65%, with no median reached. These results suggest that the combination of Thymo-
globulin, tacrolimus, and sirolimus in patients undergoing unrelated hematopoietic stem cell transplantation
is well tolerated and associated with a low incidence and severity of aGVHD and chronic graft-versus-host
disease.
Biol Blood Marrow Transplant 18: 1734-1744 (2012)  2012 American Society for Blood and Marrow TransplantationKEY WORDS: aGVHD, Unrelated hematopoietic stem cell transplantation, Antithymocyte globulin, Tacro-
limus, Sirolimus1Blood and Marrow Program, Department of Oncology,
e State University/Karmanos Cancer Center, Detroit,
gan; 2Division of Hematology/Bone Marrow Transplan-
, Markey Cancer Center, University of Kentucky,
gton, Kentucky; 3City of Hope National Medical
r–Southern California Kaiser Permanente Bone Marrow
plant Program, Duarte, California; 4Biostatistics Core,
rtment of Oncology, Wayne State University/Karmanos
r Center, Detroit, Michigan; 5Clinical Trials Office,
e State University/Karmanos Cancer Center, Detroit,
gan; and 6Department of Immunology andMicrobiology,
e State University, Detroit, Michigan.
isclosure: See Acknowledgments on page 1742.
dence and reprint requests: Zaid Al-Kadhimi, MD,
anos Cancer Center/Wayne State University, Blood and
w Program, 4100 John R, Detroit, MI 48201 (e-mail:
iz@karmanos.org).
pril 19, 2012; accepted June 6, 2012
erican Society for Blood and Marrow Transplantation
/$36.00
oi.org/10.1016/j.bbmt.2012.06.004INTRODUCTION
Graft-versus-host disease (GVHD) is the major
complication of allogeneic hematopoietic stem cell
transplantation (HSCT) and a leading cause of mor-
bidity and mortality posttransplantation. Factors that
influence the incidence and severity of GVHD in-
clude: peripheral blood stem cells, unrelated donors,
and transplantations from human leukocyte antigen
(HLA) mismatched donors [1-4]. Methods to
decrease the incidence of GVHD have relied
primarily on pharmacologic immunosuppression,
which at most centers consists of a combination of
methotrexate (MTX) and a calcineurin inhibitor
either cyclosporine A (CSA) or tacrolimus (Tac). In
spite of the use of these agents, the rate of grade II to
IV acute GVHD (aGVHD) ranges from 35% to
50% with matched related donors and up to 70% in
unrelated hematopoietic stem cell transplantation
(UHSCT) [3,5,6]. Additionally, MTX is associated
with significant mucositis, delayed engraftment, and
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Therefore, safer and more efficacious agents for the
prevention of GVHD are needed for improved
patient outcomes.
Sirolimus (Siro) is an inhibitor of the mammalian
target of rapamycin. It binds to FK506 binding pro-
tein 12 and has multiple mechanisms of immune sup-
pression, including inhibition of signal transduction
pathway response to cytokines and T cell prolifera-
tion. In addition, Siro can expand regulatory T cells
leading to further inhibition of alloreactivity [11-15].
The combination of Tac and Siro has shown
promise in reducing aGVHD in matched related
transplantations, as well as fully matched 8/8
unrelated donor transplantations [16-18]. Although
these results were encouraging, the rate of chronic
GVHD (cGVHD) was still high (59.3%), and no
HLA 7/8 matched unrelated donors were included.
Furthermore, concerns have been raised regarding
the risk of thrombotic microangiopathy (TMA) and
sinusoidal obstructive syndrome (SOS) when Tac/
Siro were combined with myeloablative doses of
busulfan as part of the busulfan/cyclophosphamide
(Bu/Cy) preparative regimen [17,19].
Thymoglobulin (Thymo) is a purified, pasteur-
ized, gamma immune globulin, obtained by immuni-
zation of rabbits with human thymocytes. This
immune-suppressive polyclonal Ab has a defined spec-
ificity against functional molecules on lymphocytes.
When added to CSA and MTX in randomized trials
of UHSCT, Thymo (a dose of 7.5 mg or 15 mg/kg
total) showed some promise in reducing both aGVHD
and cGVHD. However, the high rate of infections and
transplantation-related mortality did not result in im-
proved survival [20]. Nevertheless, the addition of
a lower dose of Thymo (4.5 mg/Kg total) to CSA
and MTX in a phase II trial of matched related
HSCT, resulted in a low rate of aGVHD as well as en-
couraging nonrelapse mortality [21].
We hypothesized that the addition of a lower
dose of Thymo to Tac and Siro could potentially
improve the incidence and severity of both
aGVHD and cGVHD in UHSCT without increasing
transplantation-related toxicities. We performed a
prospective phase II trial with this combination and in-
cluded patients who underwent UHSCT from HLA
8/8 and 7/8 matched unrelated donors. We were able
to demonstrate low cumulative incidence of both
aGVHD and cGVHD without the prohibitive inci-
dence of infections or nonrelapse mortality (NRM).METHODS
Clinical Trial
This phase II trial was approved by Wayne State
University Institutional Review Board, and all patientssigned informed consents. The trial was registered
at clinicaltrials.gov #NCT00691015. The primary
endpoint of the trial was to assess the incidence and
severity of aGVHD based on the consensus grading
scale [22]. Secondary endpoints included safety of
this combination defined as grade III or higher nonhe-
matologic toxicities as per the Common Terminology
Criteria for Adverse Events V3 and NRM in the first
6 months posttransplantation. Additional secondary
endpoints included time to absolute neutrophil count
(ANC) engraftment defined as the first of 3 consecu-
tive days, in which ANC .0.5  109/L, respectively;
time to platelet engraftment defined as the first of 3
consecutive days, in which platelets .20  109/L;
incidence of infections including cytomegalovirus
(CMV), Epstein Barr virus (EBV) reactivation,
and posttransplantation lymphoproliferative disorder
(PTLD); incidence of TMA (defined as anemia throm-
bocytopenia, acute renal impairment, and high lactate
dehydrogenase) and SOS; incidence and severity of
cGVHD using National Institute of Health consensus
[23], overall survival (OS), and progression-free sur-
vival (PFS) at 1-year posttransplantation.
Eligibility for the trial required a diagnosis of
hematologic malignancies including myelodysplastic
syndromes (MDS) and myeloproliferative disorders.
Patients without HLA matched sibling donors were
eligible if they had a suitable HLA 8/8 (A, B, C, and
DR) or 7/8 matched unrelated donor based on high
resolution typing with only one antigen or one allele
mismatch. Patients were required to have adequate or-
gan function including creatinine clearance more than
50 mL/min, left ventricular ejection fraction more
than 50%, and pulmonary function values (forced vital
capacity, forced expiratory volume in 1 second, and
carbon monoxide diffusing capacity) more than 50%
predicted.Disease Diagnosis and Risk Definitions
Diseases at high risk for relapse and death post-
transplantation were defined based on criteria set
by the Center for International Blood and Marrow
Transplant Research (CIBMTR), with few additions
(based on published data). High-risk disease included
leukemia (acute myelogenous leukemia [AML], acute
lymphoblastic leukemia [ALL], and chronic myeloge-
nous leukemia) greater than the first complete remis-
sion (.CR1) or greater than the first chronic phase,
MDS refractory anemia with excess blasts, chronic
myelomonocytic leukemia (CIBMTR criteria),
therapy-related MDS/AML, AML arising from MDS
[24-29], myelofibrosis with blasts in the peripheral
blood and/or Karnofsky Performance Scale\90% at
the time of transplantation [30], chemo resistant lym-
phoma at the time of transplantation (CIBMTR), nat-
ural killer/T cell lymphoma and lymphoma with prior
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leukemia with bulky lymphadenopathy ($5 cm), and/
or less than partial response after the last chemother-
apy treatment [32,33]. Finally, multiple myelomas
were considered high risk if there was progression
post autologous transplantation [34]. All other patients
were considered to have low-risk disease.
Preparative Regimens
Choice of preparative regimen was assigned ac-
cording to disease diagnosis, disease status, age, and
comorbidities as follows.
(A) Full-intensity regimens included: (1) Bu/flu-
darabine (Flu) full-intensity regimen consisted of bu-
sulfan 130 mg/m2 (day 26 to 23), Flu 30 mg/m2
(day 26 to 22) for myeloid disorders; (2)
BEAM 6 R regimen consisted of carmustine 300
mg/m2 (day 27), etoposide (VP16), cytarabine both
at 200 mg/m2/day (days 26 to 23), and melphalan
140 mg/m2 (day 22), and 6 rituximab 375 mg/m2
(day28), for lymphomas; (3) TBI/VP16 regimen con-
sisted of total body irradiation (TBI) 1,200 cGy (days
27 to 24) and VP16 60 mg/m2 (day 23) for ALL.
(B) Reduced-intensity regimens included (1) Bu/
Flu/TBI reduced-intensity regimen consisted of Bu
130 mg/m2 (day 26 & 25), Flu 30 mg/m2 (day 26
to 22), and TBI 200 cGy (day 0) for myeloid disor-
ders and some lymphoid malignancies with prior
autologous transplantation; (2) Flu/Mel/TBI reduced
intensity regimen consisted of Flu 30 mg/m2 (day 26
to 22), melphalan 140 mg/m2 (day 22), and TBI 200
cGy (day 0) for myeloid and lymphoid disorders.
GVHD Prophylaxis
A total dose of Thymo of 4.5 mg/kg was given
in divided doses (day 23: 0.5 mg/kg; day 22: 1.5
mg/kg; and day 21: 2.5 mg/kg). The last dose of
Thymo was administered within 24 hours of the graft
infusion. Tac was administered i.v. (0.03 mg/kg/day)
starting on day23 and was converted to oral adminis-
tration (approximately 4 times the i.v. dose) once the
patient demonstrated adequate oral intake after en-
graftment. Siro was initiated on day 23 with an oral
12 mg loading dose, followed by 4 mg/daily beginning
on day22 onward. Tac and Siro levels were measured
at least twice weekly during the first 30 days posttrans-
plantation and then at least weekly until day 100.
Doses were adjusted to achieve a therapeutic target
range of 5 to 10 ng/mL for Tac and 3 to 12 ng/mL
for Siro. Tapering of immunosuppressive therapy
was at the discretion of the treating physician and ac-
cording to the following guidelines: if no GVHD
was observed, simultaneous 25% reduction per month
of both Tac and Siro starting at 1 month posttrans-
plantation for high-risk and 3 months posttransplanta-
tion for low-risk disease (as defined above). Inaddition, tapering or cessation of immunosuppressive
therapy was permitted for relapsed malignancy in an
effort to induce a graft-versus-tumor effect.
Supportive Care
All peripheral blood stem cell (PBSC) donors were
mobilized as per the National Marrow Donor Pro-
gram standards. All recipients received granulocyte
colony-stimulating factor 5 mg/kg starting at day 16
until engraftment. Hematopoietic stem cells (HSCs)
were infused on day 0. Antimicrobial prophylaxis con-
sisted of norfloxacin, acyclovir, and fluconazole. CMV
was surveyed weekly by blood PCR. Patients with ris-
ing PCR titers were treated with preemptive ganciclo-
vir. Pneumocystis prophylaxis was started day 21
posttransplantation with double-strength trimetho-
prim/sulfamethoxazole administered twice weekly.
EBV surveillance with weekly blood PCR was started
on day 120 and continued until day 1120 posttrans-
plantation. Patients with EBV viral load .1,000
genome copy/mL received one dose of rituximab 375
mg/m2. One week later, a second dose of rituximab
was given if there was no decrease in viral load.
The aGVHD therapy was at the discretion of the
treating physician. Initial therapy of stage 1 to 2 skin
aGVHDgenerally consisted of topical corticosteroids.
Methylprednisolone or equivalent (1-2 mg/kg/day)
was started for patients with grade II or higher
aGVHD. Other immunosuppressive agents were
added as clinically indicated to treat aGVHD and
cGVHD.
Statistical Analysis
A single-arm optimal 2-stage Simon design was
used. The primary endpoint was the cumulative inci-
dence of grade II to IV aGVHD. The distinction be-
tween aGVHD and cGVHD was based on clinical
manifestations rather than time of onset posttrans-
plantation [23]. Sample size calculation was based on
the expected 40% incidence of grade II to IV aGVHD,
which reflects a one-third reduction of the historical
60% incidence rate at the Karmanos Cancer Institute.
The trial was designed with 17 evaluable patients in
stage 1 and 24 evaluable patients in stage 2 (calculated
in Power Analysis and Sample Size software) with
a5 0.05 and 80% power. Assuming a 15% loss of pa-
tients during follow-up, 20 patients were accrued in
stage 1 and 28 in stage 2, totaling 48 patients. The
stopping rule for lack of efficacy was defined as 10 or
more instances of grade II to IV aGVHD among the
first 17 evaluable patients (surviving more than 7
days after transplantation and not lost to follow-up).
If the trial proceeded to the second stage and a total
of 20 or more grade II to IV aGVHD were encoun-
tered among 41 evaluable patients, the treatment
would be considered ineffective. The cumulative
Table 1. Patient Characteristics (N 5 47)
Number
Median (range) patient age (yrs) 53 (20-70)
Sex
Male 30 (64%)
Female 17 (36%)
Diagnosis
AML 21 (45%)
CR1 5
>CR1 16
MDS 10 (21%)
RA/RARS/RCMD 4
RAEB/t-MDS 6
ALL 4 (9%)
CR1 1
>CR1 3
MFB (all high risk) 3 (6%)
CML CP1 2 (4%)
CMML 2 (4%)
NHL 2 (4%)
NK/T 1
DLBCL 1
MM 2 (4%)
Overall disease risk
Low 14 (30%)
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disease relapse or death without GVHD as competing
risks. For calculating the cumulative incidence of
grade III or IV aGVHD, the event of disease relapse
or death without aGVHD was counted as competing
risks. All lower-grade aGVHD events were ignored.
PFS was defined as the time from transplantation
to relapse or progression or death from any cause.
OS was defined as the time from transplantation to
death from any cause. Patients alive without relapse
were censored at the date of last contact. Descriptive
analyses for baseline characteristics were performed.
Incidence rates of infections were estimated using pro-
portions and the Wilson’s 95% confidence interval
(95% CI). Time-to-event endpoints, such as PFS and
OS, were estimated using the Kaplan-Meier method.
The cumulative incidence of NRM calculation had
death due to relapse as a competing risk. As for the cu-
mulative incidence of disease relapse, death without
relapse was used as a competing risk.High 33 (70%)
Full-intensity chemotherapy regimen
Bu/Flu 30 (64%)
VP16-TBI 3 (6%)
R-BEAM 1 (2%)
Low-intensity chemotherapy regimen
Bu/Flu/TBI 10 (21%)
Flu/Mel/TBI 3 (6%)
HLA matched unrelated donor
7/8 25 (53%)
8/8 22 (47%)
Median (range) donor age (yrs) 30 (19-61)
Donor/recipient sex match
F/F 7 (15%)
F/M 15 (32%)
M/F 10 (21%)
M/M 15 (32%)
Donor/recipient CMV status
+/+ 13 (28%)
+/2 5 (11%)
2/+ 13 (28%)
2/2 16 (34%)
AML indicates acute myelogenous leukemia; CR1, first complete remis-
sion; MDS, myelodysplastic syndrome; RA/RARS/RCMD, refractory
anemia/refractory anemia with ringed sideroblasts/refractory cytopenia
with multilineage dysplasia; RAEB, refractory anemia with excess blasts;
ALL, acute lymphoblastic leukemia; MFB, myelofibrosis; CML, chronic
myelogenous leukemia; CP1, chronic phase; CMML, chronic myelomo-
nocytic leukemia; NHL, non-Hodgkin lymphoma; NK/T, natural killer/
T cells; DLBCL, diffuse large B cell lymphoma; MM, multiple myeloma;RESULTS
Patient Characteristics
Between July 2008 and November 2010, 48 pa-
tients were accrued to the trial. One patient was not
evaluable because she refused the third dose of Thymo.
Patients’ demographics are summarized in Table 1.
The median patient age was 53 years (range, 20-70
years), with 30 men and 17 women participating.
The median donor age was 30 years (range, 19-61
years), with 25 men and 22 women donating. The
most common diagnosis was AML (44.6%), followed
by MDS (21.2%). The most common preparative reg-
imen was Bu/Flu (63.8%), followed by low-intensity
Bu/Flu/TBI (21.2%). Twenty-two patients (47%) re-
ceived PBSC cells from 8/8 HLA matched unrelated
donors, whereas 25 patients (53%) received PBSC cells
from 7/8 HLA matched unrelated donors. Four pa-
tients underwent a prior autologous transplantation.
A total of 33 patients (70.2%) had a high-risk disease
for relapse and death as defined above.Bu/Flu, busulfan/fludarabine; TBI, total body irradiation; R-BEAM,
rituximab/carmustine/etoposide/cytarabine/melphalan; F/F, female to fe-
male; F/M, female to male; M/F, male to female; M/M, male to male; CMV,
cytomegalovirus.Drug Levels
Among the 47 evaluable patients on study, there
was a median of 13 measurements for Tac (range,
2-20) and 11 measurements for Siro (range, 6-19) dur-
ing the first 30 days posttransplantation. The median
Tac level was 8.8 ng/mL (interquartile range, 8.0-
9.9) and Siro level was 4.7 ng/m: (interquartile range,
3.9-6.4) during the first 30-days posttransplantation.
For Tac and Siro, 14% and 18% of the first 30-day
measurements were below the target range, respec-
tively, whereas 25% and 7% of the readings were
above the target range, respectively. Six patients hadtheir Tac discontinued before day 30 due to headaches
(n5 3, switched to cyclosporine) and renal impairment
(n5 3). Both Tac and Siro were discontinued in a total
of 5 patients before day 30 due to SOS (n 5 2), TMA
(n 5 1), and renal impairment (n 5 2).
Engraftment
The median number of CD341 stem cells infused
was 7.3 10 6/kg (range, 1.9-18.6). The median day to
1738 Biol Blood Marrow Transplant 18:1734-1744, 2012Z. Al-Kadhimi et al.ANC engraftment was 11 (range, 9-15), and platelet
engraftment was 17 (range, 0-26). Chimerism of pe-
ripheral blood by short tandem repeat analysis at day
100 showed greater than 95% donor chimerism in
94% of the patients in the lymphoid and 100% of
the patients in the myeloid line. There was one case
of late graft failure beyond day 100, in which the pa-
tient developed pancytopenia, hypocellular marrow
with peripheral blood, and bone marrow (BM) still
showing 100% donor chimerism.
Graft-versus-Host Disease
A total of 11 patients developed grade II to IV
aGVHD, with a cumulative incidence of 23.4%
(95% CI, 12.4-36.3; Figure 1A). Three of these pa-
tients were 8/8 HLA matched, whereas 8 were 7/8
HLA matched. The median time to the development
of grade II to IV aGVHD was 39 days (range, 16-
179 days). Six patients developed grade III to IV
aGVHD with a cumulative incidence of 12.8% (95%
CI, 5.1-24.0; Figure 1B). Two of these patients were
8/8 HLA matched, whereas 4 were 7/8 HLA matched.
Two patients developed aGVHD beyond day 100.
Four of 6 patients with grade III to IV aGVHD had
interruption in Tac and/or Siro before day 30, as
described above. Organ distribution and stage of
aGVHD is shown in Table 2. With a median follow-
up of 2 years, 16 patients developed cGVHD (National
Institutes of Health consensus criteria) [23] with a
cumulative incidence of 33% (95% CI, 19.5-47.1;
Figure 2). There were 8 mild, 7 moderate, and 1 severe
case of cGVHD (bronchiolitis obliterans). Four pa-
tients died from aGVHD complications, and 1 patient
died from cGVHD.Figure 1. Cumulative incidence of acute graft-versus-host disease (aGVHD)
grade II-IV aGVHD. Panel B shows grade III-IV aGVHD.Toxicity
Protocol-related toxicities are summarized in
Table 3. The highest grade of mucositis was grade
III (Common Terminology Criteria for Adverse
Events v 3) and was observed in 16 patients (34%).
Three patients developed SOS.One patient had recent
gemtuzumab ozogamycin exposure and had Bu/Flu
full-intensity preparative regimen. The other 2 pa-
tients had previous autologous SCT and received
Flu/Bu/TBI low-intensity regimen. One patient re-
covered, whereas 2 patients died. Two patients devel-
oped TMA, both of whom were on voriconazole for
fungal infection prevention. One patient died, whereas
the other patient improved with supportive measures.
All patients with SOS and TMA had a high level of
Siro before the onset (range, 11.6-23 ng/mL). One pa-
tient developed idiopathic pneumonia syndrome and
died from progressive respiratory failure. The cumula-
tive incidence of NRM at 6 and 24 months was 21.3%
(95% CI, 10.9-34.0) and 31.9% (95% CI, 18.4-46.2),
respectively (Figure 3).
Infections
The rates of infectious occurrences are summarized
inTable 3. Sixteen patients (34%) had PCRCMVvire-
mia without CMV disease. Ten patients (21.8%) had
EBV PCR reactivation with no clinical PTLD. EBV
reactivation resolved after treatment with rituximab
in all patients. Thirty-one patients (66%) developed
bacterial infections.Only one case of bacteremia (Kleb-
siella pneumonia) was a primary event and considered
a grade IV toxicity requiring intensive care unit admis-
sion for sepsis. Eight episodes of bacteremia occurred
concomitantly with severe GVHD or multiorganafter unrelated hematopoietic stem cell transplantation. Panel A shows
Table 2. Distribution of Maximum aGVHD
aGVHD Overall Grading Number 5 47 (%)
0 27 (57)
1 9 (19)
2 5 (10)
3 2 (4)
4 4 (8)
Skin
0 33 (70)
1 10 (21)
2 3 (6)
3 1 (2)
4 0 (0)
Liver
0 43 (91)
1 0 (0)
2 1 (2)
3 1 (2)
4 2 (4)
Upper GI
0 38 (80)
1 9 (19)
Lower GI
0 38 (80)
1 4 (8)
2 1 (2)
3 1 (2)
4 3 (6)
aGVHD indicates acute graft-versus-host disease; GI, gastrointestinal.
Table 3. Toxicity and Infectious Occurrences
Clinical Outcome Occurrence n 5 47 Rate (95% CI)
Mucositis (III) 16 0.34 (0.22-0.48)
SOS 3 0.06 (0.02-0.17)
TMA 2 0.04 (0.01-0.14)
CMV PCR 16 0.34 (0.22-0.48)
EBV PCR 10 0.21 (0.12-0.35)
HSV stomatitis 9 0.19 (0.10-0.33)
BK cystitis 10 0.21 (0.12-0.35)
Bacterial infections 31 0.66 (0.52-0.78)
Oral candidiasis 4 0.09 (0.03-0.20)
CI indicates confidence interval; SOS, sinusoidal obstruction syndrome;
TMA, thrombotic microangiopathy; CMV, cytomegalovirus; EBV,
Epstein–Barr virus.
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staphylococcus bacteremia, and 6 patients had clostridium
difficile infections. There were no invasive fungal infec-
tions apart from oral candidiasis (n5 4). Infection was
not the primary cause of death in any patient. We ob-
served that patients (n5 6) who received systemic ste-
roids in the first 30 days posttransplantation (for
bridging, engraftment syndrome, or presumed
aGVHD) developed multiple infections (viral and bac-
terial) in the first 100 days posttransplantation.
Relapse
A total of 12 patients have relapsed with a
cumulative incidence of relapse at 24 months ofFigure 2. Cumulative incidence of chronic graft-versus-host disease
(cGVHD). UHSCT, unrelated hematopoietic stem cell transplantation.24.6% (95% CI, 12.9-38.2; Figure 4). Eleven of these
12 patients had high-risk disease. Five relapses oc-
curred in patients who received a low-intensity
preparative regimen, 3 of whom had a prior trans-
plantation. Five relapses occurred before day 100, 4
relapses occurred between day 100 and 1 year, and
3 occurred after 1-year posttransplantation. CR
was achieved in 2 recipients who had relapsed AML
and non-Hodgkin lymphoma upon withdrawal of
immune suppression and occurrence of GVHD.
However, one patient relapsed 3 months later and
died. The second recipients died 16 months later
from severe cGVHD.Large Granular Lymphocytosis
Eight patients developed large granular lymphocy-
tosis (LGL) posttransplantation (17%) [35]. All cases
presented with lymphocytosis (.20  109/L), with
no associated cytopenia or autoimmune manifesta-
tions. Median day of occurrence was 266 (range, 69-
384 days) posttransplantation. All 8 patients had large
granular lymphocytes observed in their peripheral
blood. Peripheral blood flow cytometry showed aFigure 3. Cumulative incidence of nonrelapse mortality. UHSCT, unre-
lated hematopoietic stem cell transplantation.
Figure 4. Cumulative incidence of relapse. UHSCT, unrelated hemato-
poietic stem cell transplantation.
Table 4. Causes of Death
Cause of Death Number 5 20
Relapse 7 (35%)
aGVHD 4 (20%)
Multiorgan failure 3 (15%)
SOS 2 (10%)
cGVHD 1 (5%)
TMA 1 (5%)
Idiopathic pneumonia syndrome 1 (5%)
Graft failure 1 (5%)
aGVHD indicates acute graft-versus-host disease; SOS, sinusoidal ob-
struction syndrome; cGVHD, chronic graft-versus-host disease; TMA,
thrombotic microangiopathy.
1740 Biol Blood Marrow Transplant 18:1734-1744, 2012Z. Al-Kadhimi et al.population of CD45, CD2, CD3, CD5, CD7, CD8,
and CD57 positive T cells. In 5 of 8 patients, T cell
receptor gene rearrangement was detected by PCR.
All recipients were CMV positive, whereas only 4
donors were CMV positive pretransplantation. In all
8 patients, there was a detectable CMV by PCR pre-
ceding the occurrence of LGL. GVHD occurred in
4 of 8 patients before LGL diagnosis. Two patients re-
lapsed and died with primary disease, whereas the rest
are alive and disease free.
Survival and Outcomes
With a median follow-up of 23.6 months (range,
7.8-34.7 months), the OS at 100 days and 1-year
posttransplantation was 78% and 65%, respectively
(Figure 5).The median survival for the whole group
has not been reached. PFS at 100 days and 1-year post-
transplantation was 72% and 54%, respectively. The
median PFS was 17.7 months (Figure 5). Causes of
death are summarized in Table 4. The most frequent
causes of death were relapse (n 5 7), aGVHD
(n 5 4), multiorgan failure (n 5 3), and SOS (n 5 2).Figure 5. Progression-free survival (PFS) and overall survival (OS).
BMT, bone marrow transplantation.DISCUSSION
We report the first prospective trial to evaluate
a novel combination of intermediate dose Thymo,
Tac, and Siro for the prevention of GVHD in the
recipients of UHSCT. The cumulative incidence of
grade II to IV and grade III to IV aGVHD was
23.4% and 12.4%, respectively. Considering that
more than half of the patients (n 5 25) received 1
antigen mismatched graft (HLA 7/8), this is a very en-
couraging finding. Previous aGVHD prevention trials
showed up to 70% grade II to IV aGVHD in unrelated
transplantations [36-41]. Although further follow-up
is needed, the cumulative incidence of cGVHD was
low (33%) at 2 years.
The rationale for using the combination of
Thymo, Tac, and Siro for GVHD prevention was
based on studies showing the efficacy of Tac and Siro
for the prevention of aGVHD, as well as separate stud-
ies showing the efficacy of Thymo in reducing the in-
cidence of cGVHD. The clinical synergy between Tac
and Siro in aGVHD prevention was first observed by
Cutler et al. [16] in a cohort of 30 patients who under-
went an HLA matched sibling transplantation with
Cy/TBI full-intensity preparative regimen. The cu-
mulative incidence of grade II to IV aGVHD was
10% with no grade III to IV observed. Their rates of
TMA and SOS were 13% and 10%, respectively. In
a follow-up report, which included 30 patients who re-
ceived HLA 8/8 matched unrelated transplantations,
the cumulative incidence of grade II to IV aGVHD
was 23.3%; however, cGVHD was still high at
59.3% [18]. The same investigators cautioned that
a high rate of SOS is associated with the use of Siro
in the context of myeloablative regimens containing
Bu [19]. Roriguez et al. [17] used Tac/Siro in related
transplantations and reported a higher incidence
of aGVHD grade II to IV (43%), grade III to IV
(19%), and cGVHD (51%). He also observed a higher
incidence of TMA in the Bu/Cy group, which led to
early closure of that arm to accrual. Additional studies
have looked at the addition of MTX to a combination
of a calcineurin inhibitor and Siro. In 2003, Antin et al.
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mini-MTX in 41 patients who underwent UHSCT,
all of whom received BM SCT after Cy/TBI prepara-
tive regimen. The incidence of grade II to IV aGVHD
was 26%, grade III to IV was 13%, and 1-year OS was
52%. Later, Furlong et al. repeated a similar design in
two consecutive clinical trials of GVHD prophylaxis
with few differences: standard dose MTX instead of
mini MTX, TBI followed by Cy instead of the reverse,
and PBSC instead of bone marrow. The first trial was
with CSA/Siro (n 5 9), whereas the second trial was
with Tac/Siro (n 5 17). A higher rate of aGVHD
grade II to IV of 77% was observed in addition to
higher toxicity, which led to early termination of ac-
crual in both studies. It is not clear based on these trials
if MTX would have additional efficacy for the preven-
tion of GVHD when added to combinations of calci-
neurin inhibitors and sirolimus. Compared to the
patients who underwent UHSCT in the Cutler report,
our phase II trial showed a similar low rate of aGVHD,
despite the fact that more than half of our patients re-
ceived a transplantation from a 7/8 matched unrelated
donor. In addition, the incidence and severity of
cGVHD in our trial seems lower than what was re-
ported (Table 5).
The use of Thymo as part of an aGVHD prophy-
laxis regimen in UHSCT has been evaluated in the last
decade with varying outcomes. In 2001, Bacigalupo
et al. [43] evaluated in a randomized clinical trial,
the addition of Thymo (7.5 mg/kg or 15 mg/kg) pre-
transplantation to CSA and MTX. All patients re-
ceived unrelated BM grafts. The higher-dose Thymo
arm had a significantly lower incidence of grade III
to IV aGVHD compared to CSA/MTX alone (11%
vs 50%; P 5 .001). However, high transplantation-
related mortality due to infections was observed in
both Thymo arms (39% for the 7.5 mg/kg and 62%Table 5. Comparable Trials for aGVHD Prophylaxis
Study aGVHD Prophylaxis Regimen
Number of
Patients Graft Type G
Cutler 2003 Tac/Siro Cy/TBI 30 PBSC
Cutler 2007 Tac/Siro Cy/TBI 30 PBSC
Rodriguez 2009 Tac/Siro Multiple 85 PBSC
Antin 2003 Tac/Siro Mini-MTX Cy/TBI 41 BM
Furlong 2008 Tac or CSA Siro/MTX TBI/Cy 26 PBSC
Bacigalupo 2001 CSA/MTX ± Thymo Cy/TBI 56† BM
Rodriguez 2010 CSA/MMF/Thymo Flu/Mel 24 95% PBSC
Finke 2009 CSA/MTX ± ATG-F Multiple 103† PBSC or BM
Al-Kadhimi 2012 Tac/Siro Thymo Multiple 47 PBSC
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic graft-vers
TBI, total body irradiation; PBSC, peripheral blood stem cell; MRD, match
methotrexate; BM, bone marrow; RD, related donor; CSA, cyclosporine A;
Mel, melphalan; ATG-F, rabbit antithymocyte globulin Fresenius preparation.
*By serology or intermediate resolution molecular typing for MHC class I and
†In the experimental arm.
‡Donors were matched by serology for HLA-A and HLA-B, including split ant
§For Thymo dose of 7.5 mg/kg and 15 mg/kg, respectively, in the experimenta
jjHLA-C mismatch in 20% of patients in the experimental arm.for the 15 mg/kg at 3 years). Therefore, no improve-
ment in OS was observed at 3 years of follow-up
[20]. In 2006, an extended follow-up report showed
that Thymo prevented cGVHD, chronic lung dys-
function, and late transplantation-related mortality
(3% Thymo vs 25% control arm; P5 .03) for patients
who survived beyond 1 year. Again, no significant dif-
ference in OS was observed between the 2 groups
(44% Thymo vs 31% control; P 5 .80), at 6 years of
follow-up [43]. Socie et al. [44] made a similar observa-
tion of reduced extensive cGVHD in a European ran-
domized trial with rabbit antithymocyte globulin
Fresenius preparation (ATG-F). Patients in that trial
received a myeloablative regimen with CSA and
MTX 6 ATG-F. No significant differences were ob-
served in rates of severe aGVHD, relapse, NRM, and
survival between the 2 groups. In 2010, Rodriguez
et al. [40] reported on the combination of CSA, myco-
phenolate mofetil (MMF), and Thymo (total dose of
7.5 mg/kg) in 22 patients who underwent UHSCT.
The cumulative incidence of aGVHD grade II to IV
was 75%, and grade III to IV was 30%. At 27 months
of follow-up, OS and disease-free survival was 65%
and 60%, respectively. There was a higher rate of
EBV reactivation (40%) by PCR. All patients were
treated with rituximab with no sequels. Compared to
the above trials of in vivo T-cell depletion, our study
demonstrated, in addition to low incidence and sever-
ity of aGVHD and cGVHD, no increase in the rate of
infections or NRM (Table 5). The rationale for the in-
termediate dose of Thymo (4.5 mg/kg total) used in
our trial and the timing of the last dose (within 24
hours of graft infusion) was based on observations in
previous reports. Higher doses of Thymo were associ-
ated with high rates of transplantation-relatedmorbid-
ity and infections [20]. In addition, lower doses of
Thymo (2.5 mg/kg total) were associated with highraft Source HLA Match aGVHD II to IV cGVHD NRM at 1 Year
MRD 8/8 10% 59.1% 6%
URD 8/8 23.3% 59.3% NR
MRD 8/8 43% 46% 10.2%
URD/RD 5/6 or 6/6* 26% 42% NR
URD 10/10 77% 90% NR
URD 6/6‡ 72.37%§ 39%† 27.50%§
URD 60% 10/10 75% 25% NR
URD 8/8jj 33%§ 30%† 20%†
URD 7/8 or 8/8 23% 33% 23%
us-host disease; Tac, tacrolimus; Siro, Sirolimus; Cy, cyclophosphamide;
ed related donor; URD, unrelated donor; NR, not reported; MTX,
Thymo, Thymoglobulin; MMF, mycophenolate mofetil; Flu, fludarabine;
by high-resolution molecular techniques for MHC class II.
igens, and by high-resolution molecular biology for HLA-DRB1.
l arm.
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Thymo within 24 hours of graft infusion allowed
a higher serum level on day zero, which seemed to cor-
relate with less aGVHD [46].
The rate of SOS occurrence in our trial was low
at 6% (n 5 3). All 3 patients had risk factors for
SOS (ie, gemtuzumab ozogamycin or prior auto-
transplantation). There was a low occurrence of
TMA before day 100 (n 5 2), with only one TMA-
related death. These rates are lower than previously
reported [17,19]. To our knowledge, this is the first
trial to demonstrate the safety of using Siro with full-
intensity doses of Bu. High levels of Siro were
observed in all patients before the development of
TMA or SOS. An association between higher Siro
levels and TMA/SOS occurrence has been observed
by Rosenbeck et al. [47]. Somewhat unique to T-cell
depletion [43,44], we observed a 21% rate of EBV
reactivation by PCR only. However, all patients have
responded to 1 or 2 doses of rituximab, with no
development of PTLD. Again, this is lower than
previously reported with the CSA/MMF/Thymo
trial (41%) [40]. We did, however, notice an increased
risk of multiple infections in patients who received sys-
temic steroids in the first 30 days posttransplantation.
Therefore, we subsequently attempted to taper ste-
roids more rigorously when possible. We observed
no clinical CMV or mold infections in this group of
patients, and no patients had infection as the primary
cause of death. We suspect that the lower dose of
Thymo used in this trial might have contributed to
keeping the rate of infections low.
Although the majority of the patients (70%) were
at high risk for relapse, as defined above, we observed
a relatively low cumulative incidence of relapse of
24.6% at 2 years. This compares well with other trials
for aGVHD prophylaxis [20,37,44]. Relapse was the
leading cause of death on protocol. Interestingly,
we observed the highest reported rate of LGL
occurrence in our patient series with 8 of 47
evaluable patients (17%). Mohty et al. [35] described
6 LGL cases in a retrospective series of 201 consecu-
tive patients over 7 years (0.029%). LGL was associ-
ated with chronic antigenic stimulation especially
CMV infection and GVHD, as well as possibly less
risk of relapse [35,48,49]. Although 6 of these 8
patients in our trial are alive and disease free, the
clinical significance of this observation is unclear at
this point. We report an encouraging PFS of 54%
and OS of 65% at 1 year. This compares well with
other published GVHD prophylaxis trials, in light of
the large proportion of high-risk disease and HLA
mismatched transplantations in our group of patients
[20,36,37,43].
This trial was designed to be inclusive of all pa-
tients undergoing unrelated transplantations at our
institution. Patients received different preparative reg-imens based on their disease and disease status. The
heterogeneity of disease and preparative regimen is a
limitation of this phase II trial. Whether these differ-
ences influenced disease-specific outcomes is not
easy to define, given our small patient population. Fur-
thermore, we suspect that maintaining a therapeutic
level of Tac and Siro is a key contributor to better
outcomes. Two-thirds of patients with grade III to
IV aGVHD had interruption of Siro and/or Tac be-
fore day 30 posttransplantation. In addition, virtually
all incidences of SOS/TMA were preceded by high
Siro levels. We predict that closer attention to drug
levels, drug interactions, and renal function may
contribute to better achievement of therapeutic levels
of Tac and Siro in the first 30 days posttransplantation,
and eventually further improvement in aGVHD and
NRM.
In summary, the triple combination of (intermedi-
ate dose) Thymo/Tac/Siro produced low rates and
severity of both aGVHD, cGVHD, as well as encour-
aging transplantation outcomes in a cohort of patients
at high risk for GVHD and relapse. Future avoidance
of both high and low Tac/Siro levels, as well as
limiting the exposure to high-dose steroids in the
first 30 days posttransplantation may further reduce
transplantation-related complications and improve
outcomes. Further testing of this combination in a
randomized phase III trial using a homogeneous pre-
parative regimen and patient population may further
prove its efficacy.ACKNOWLEDGMENTS
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